OpenAI acquires Orchestra Bio to integrate AI-driven agents into drug development workflows. Orchestra’s technology automates study monitoring, financial tracking, and clinical trial scheduling, addressing inefficiencies in pharmaceutical pipelines. The startup’s tools will now operate under OpenAI’s Rosalind unit, which partners with drugmakers like Novo Nordisk and Moderna to accelerate research. Orchestra Bio was founded in 2022 by CEO Ashoka Rajendra and secured $20M in seed funding from investors including Andreessen Horowitz.
OpenAI acquires Orchestra Bio, a biotech startup specializing in AI agents for pharmaceutical drug development pipelines. The move expands OpenAI’s capabilities in applying AI to life sciences, targeting efficiency gains in clinical trials and compound discovery. Orchestra Bio’s technology focuses on automating and optimizing drug development workflows for industry partners.
OpenAI and other well-funded AI startups are using acquisitions to broaden products, enter markets and add specialized teams, Crunchbase data shows. Through Sept. 29, the data tracks 195 acquisitions of AI startups by other venture-backed AI companies, 14% more than in all of 2025, while the number of buyers grows just 2%. Over three years, 67 repeat buyers account for about 42% of tracked deals; OpenAI leads with 20 acquisitions, including 10 this year.
Oct 2026Crunchbase NewsNews article
Coefficient Bio
Coefficient Bio was a stealth AI biotech startup applying AI to drug discovery research.
